A 6-week, Randomised, Multi-centre, Open-labelled, Parallel Group, Exploratory Trial to Investigate the Safety of SIAC Compared to Mix30 (NovoRapid 30Mix) on a Twice Daily Regimen in Subjects With Type 2 Diabetes Mellitus
Phase of Trial: Phase II
Latest Information Update: 11 Feb 2017
At a glance
- Drugs Insulin aspart/insulin protamine aspart (Primary) ; Insulin degludec/insulin aspart (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Novo Nordisk
- 03 Jul 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 03 Jul 2009 Actual patient number (65) added as reported by ClinicalTrials.gov.
- 08 Apr 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.